 |
|
Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque Psoriasis
Alan Menter, MD;
Kenneth Gordon, MD;
Wayne Carey, MD;
Tiffani Hamilton, MD;
Scott Glazer, MD;
Ivor Caro, MD;
Nicole Li, PhD;
Wayne Gulliver, MD; for the Efalizumab Study Group
Arch Dermatol. 2005;141:31-38.
Objective To assess the efficacy and safety of a 24-week course of efalizumab.
Design Phase 3, randomized, double-blind, parallel-group, placebo-controlled 12-week study followed by a 12-week open-label study.
Setting Outpatient dermatology clinics.
Patients A total of 556 patients with moderate to severe chronic plaque psoriasis who were seeing an outpatient dermatologist were included in the study.
Intervention For weeks 1 to 12, the 556 patients were randomized to receive 1 mg/kg of efalizumab weekly or placebo subcutaneously. For weeks 13 to 24, 516 of these patients received 1 mg/kg of efalizumab weekly.
Main Outcome Measures Proportion of patients with a 75% or greater improvement in Psoriasis Area and Severity Index (PASI-75), a 50% or greater improvement in PASI (PASI-50), static Physician’s Global Assessment (sPGA) rating of minimal or clear, and improvements in Dermatology Life Quality Index (DLQI), itching scale, and Psoriasis Symptom Assessment (PSA) frequency and severity scores at weeks 12 and 24. Safety was evaluated by reviewing adverse events, laboratory parameters, vital signs, and anti-efalizumab antibodies.
Results At week 12, 26.6% of efalizumab-treated patients achieved PASI-75 and 58.5% achieved PASI-50. After 24 weeks of continuous efalizumab therapy, PASI responses increased: 43.8% of patients achieved PASI-75 and 66.6% achieved PASI-50. The percentage of patients who achieved an sPGA rating of minimal or clear increased from 25.7% to 35.9%. The mean percentage of improvement in all patient-reported outcomes (DLQI, itching scale, and PSA frequency and severity scores) at week 12 was maintained at week 24 (DLQI, 49.2%; itching scale, 42.2%; PSA frequency, 47.6%; PSA severity, 47.3%). There was a decline in overall reported adverse events from weeks 1 to 12 (80.4%) to weeks 13 to 24 (63.2%) without evidence of cumulative toxic effects.
Conclusion Extending efalizumab treatment from 12 to 24 weeks leads to improved efficacy and maintenance of quality of life with no evidence of cumulative toxic effects noted in patients with moderate to severe chronic plaque psoriasis.
Author Affiliations: Baylor University Medical Center, Dallas, Tex (Dr Menter); Loyola University Medical Center, Maywood, Ill (Dr Gordon); Royal Victoria Hospital, Montreal, Quebec (Dr Carey); Atlanta Dermatology, Vein and Research Center LLC, Atlanta, Ga (Dr Hamilton); Glazer Dermatology, Buffalo Grove, Ill (Dr Glazer); Genentech Inc, South San Francisco, Calif (Drs Caro and Li); and Newlab Clinical Research, St Johns, Newfoundland (Dr Gulliver).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Members of the National Psoriasis Foundation: More Extensive Disease and Better Informed About Treatment Options
Tamar Nijsten, Tara Rolstad, Steven R. Feldman, and Robert S. Stern
Arch Dermatol. 2005;141(1):19-26.
ABSTRACT
| FULL TEXT
Topical Tacrolimus Ointment Combined With 6% Salicylic Acid Gel for Plaque Psoriasis Treatment
Christie L. Carroll, Jan Clarke, Fabian Camacho, Rajesh Balkrishnan, and Steven R. Feldman
Arch Dermatol. 2005;141(1):43-46.
ABSTRACT
| FULL TEXT
Patient Education and Advocacy Groups: A Means to Better Outcomes?
Kenneth B. Gordon
Arch Dermatol. 2005;141(1):80-81.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Biologic Therapies for Psoriasis
de FELICE et al.
The Journal of Rheumatology Supplement 2009;83:62-64.
ABSTRACT
| FULL TEXT
Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis: Results of a Randomized, Placebo-Controlled, Phase 2 Trial
Kimball et al.
Arch Dermatol 2008;144:200-207.
ABSTRACT
| FULL TEXT
Use of Biological Agents in Patients With Moderate to Severe Psoriasis: A Cohort-Based Perspective
Jones-Caballero et al.
Arch Dermatol 2007;143:846-850.
ABSTRACT
| FULL TEXT
Efalizumab-Associated Papular Psoriasis
Hassan et al.
Arch Dermatol 2007;143:900-906.
ABSTRACT
| FULL TEXT
Successful Treatment of Severe Atopic Dermatitis in a Child and an Adult With the T-Cell Modulator Efalizumab.
Weinberg and Siegfried
Arch Dermatol 2006;142:555-558.
FULL TEXT
An Overview of the Pharmacokinetics and Pharmacodynamics of Efalizumab: A Monoclonal Antibody Approved for Use in Psoriasis
Joshi et al.
J Clin Pharmacol 2006;46:10-20.
ABSTRACT
| FULL TEXT
Efalizumab for the Treatment of Moderate to Severe Plaque Psoriasis
Jordan
The Annals of Pharmacotherapy 2005;39:1476-1482.
ABSTRACT
| FULL TEXT
|
